FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA | Delayed Börse Stuttgart 11:53:44 07/06/2024 BST | ||
| 117.3 EUR | +15.08% |
|
| Current month | +4.08% | ||
| 1 month | -9.34% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 117.3 | +15.08% |
| 06/06/24 | 102 | +24.94% |
| 05/06/24 | 81.61 | -18.72% |
| 04/06/24 | 100.4 | +0.76% |
| 03/06/24 | 99.65 | +1.73% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 11:53 am
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MB1CZN |
| ISIN | DE000MB1CZN6 |
| Date issued | 12/12/2022 |
| Strike | 488.3 kr |
| Maturity | Unlimited |
| Parity | 0.22 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 257.8 € |
|---|---|
| Lowest since issue | 5.45 € |
| Spread | 1.8 € |
| Spread % | 1.83% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
651
DKK
Average target price
785.6
DKK
Spread / Average Target
+20.67%
- Stock Market
- Certificates
- Certificat
